

NDA 205552/S-042
NDA 210563/S-018
NDA 217003/S-003

SUPPLEMENT APPROVAL

Pharmacyclics LLC
Attention: Xiaoran Xu, M.S.
Senior Manager, Regulatory Affairs
1000 Gateway Blvd
South San Francisco, CA 94080

Dear Xiaoran Xu:

Please refer to your supplemental new drug applications (sNDAs) dated and received April 18, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Imbruvica (ibrutinib) capsules, tablets, and oral suspension.

We also refer to our letter dated March 22, 2024, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we have determined should be included in the labeling for the Bruton tyrosine kinase inhibitor products. This information pertains to the risk of hepatotoxicity including drug-induced liver injury (DILI).

This supplemental new drug application provides for revisions to the labeling for Imbruvica (ibrutinib). The agreed upon changes to the language included in our March 22, 2024, letter are as follows (additions are noted by underline and deletion are noted by ~~strikethrough~~).

1. Highlights of Prescribing Information:

Recent Major Changes:

Indications and Usage, Mantle Cell Lymphoma (1.1)	
Accelerated Approval Indication Removed	5/2023
Indications and Usage, Marginal Zone Lymphoma (1.5)	
Accelerated Approval Indication Removed	5/2023
Dosage and Administration (2.1, 2.2, 2.3, 2.4)	5/2023
Warnings and Precautions, Hypertension (5.4)	5/2023
<u>Warnings and Precautions, Hepatotoxicity,</u>	
<u>including Drug-induced Liver Injury (DILI) (5.7)</u>	<u>5/2024</u>

Warnings and Precautions:

Hepatotoxicity, including Drug-induced Liver Injury (DILI): Monitor hepatic function throughout treatment (5.7).

2. Section 5, Warnings and Precautions:

5.7 Hepatotoxicity, ~~including Drug-Induced Liver Injury (DILI)~~

Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), ~~have been observed~~ occurred in patients treated with Bruton tyrosine kinase inhibitors including IMBRUVICA.

Evaluate bilirubin and transaminases at baseline and throughout treatment with IMBRUVICA. For patients who develop abnormal liver tests after IMBRUVICA, monitor more frequently ~~monitoring~~ for liver test abnormalities and clinical signs and symptoms of hepatic toxicity ~~is recommended~~. If DILI is suspected, withhold IMBRUVICA. Upon confirmation of DILI, discontinue IMBRUVICA.

3. Subsection 6.2, Postmarketing Experience:

Hepatobiliary disorders: hepatic failure including acute and/or fatal events, hepatic cirrhosis, drug-induced liver injury

4. Section 17, Patient Counseling Information:

Hepatotoxicity, including ~~Drug-Induced Liver Injury (DILI)~~:

Inform patients that liver problems, including ~~severe, life-threatening, or fatal hepatitis, DILI~~ drug-induced liver injury and abnormalities in liver tests, may develop during IMBRUVICA treatment. Advise patients to contact their healthcare provider immediately if they experience ~~fatigue, anorexia,~~ abdominal discomfort, dark urine, or jaundice [*see Warnings and Precautions (5.X7)*]."

5. Patient Package Insert:

- **Liver problems.** Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with IMBRUVICA. Your healthcare provider will do blood tests to check your liver before and during treatment with IMBRUVICA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Jessica Kim, Safety Regulatory Project Manager, at 240-402-0883, or via email at Jessica.Kim1@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Shan M. Pradhan, M.D.
Associate Director for Safety
Office of Oncologic Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert or Medication Guide
 - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SHAN PRADHAN
05/09/2024 02:11:03 PM